- We spend a lot of money on modern treatment of blood cancers, and not using Covid-19 pre-exposure therapy, we risk that an immunosuppressed patient will die of infection - says prof. Iwona Hus, deputy head of the Hematology Clinic of the Institute of Hematology and Transfusion Medicine in Warsaw, president of the Polish Society of Hematology and Transfusion Medicine.
Covid-19 mortality in this group reaches 30%
For immunocompromised patients, the coronavirus is still a lethal threat. Their bodies are unable to make antibodies after being vaccinated against Covid-19, and the disease is much more dramatic. The rescue for these patients is the administration of ready-made antibodies that protect against the development of coronavirus infection and the symptomatic course of COVID-19. Unfortunately, such prophylaxis is not available with us.
...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
